⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of SarcoMedUSA Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
SarcoMedUSA Inc.
↗Houston, USA
SarcoMedUSA is a private biotechnology company focused on developing therapeutic solutions for chronic pulmonary inflammation diseases, specifically targeting Pulmonary Sarcoidosis. The company's primary research effort involves investigating whether inhaled DNase 1 therapy can improve outcomes for patients suffering from this condition.
Founded in 2017 and headquartered in Houston, Texas, the company has assembled a team of drug development experts to advance its lead candidate, SM001 (alidornase). SarcoMedUSA has received orphan drug status from the FDA for this program and is exploring additional indications for SM001, including Adult Respiratory Distress Syndrome, Idiopathic Pulmonary Fibrosis, and Cystic Fibrosis.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2017
Ownership:private
Status:operating
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical/Early Clinical
Modalities:Small molecule, Biologic
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Roswell Park Cancer Center (Research collaboration)
COMPETITION
Position:Emerging
Competitors:Nocion Therapeutics, Attenua, Seyltx
LEADERSHIP
Key Executives:
Brian Davies - Chief Executive Officer
Ira N. Kalfus - Chief Medical Officer
Daniel Cartwright - Chairman of the Board
LINKS
Website:sarcomedusa.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with SarcoMedUSA Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.